The SNM has announcedthe formation of theMolecular Imaging ClinicalTrials Network, a multi-institutionaleffort to establishscientifically sound, efficientways to evaluate proposedclinical applicationsof biomarker imaging.
The SNM has announced the formation of the Molecular Imaging Clinical Trials Network, a multi-institutional effort to establish scientifically sound, efficient ways to evaluate proposed clinical applications of biomarker imaging.
The network will provide investigational new drugs to the pharma industry and to molecular imaging researchers to develop the next generation of diagnostic and therapeutic agents, according to SNM officials. It will also coordinate imaging protocols and equipment calibration for multicenter clinical trials.
Scientific investigation under the program should start in the first quarter of 2009.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.